Adimab
The power of integration.

February 4, 2008
Press Release

Piotr Bobrowicz, Ph.D. to join Adimab, Inc. as Associate Director of Strain Development

Lebanon, NH – February 4, 2008 – Adimab, Inc., a biotechnology startup company developing an integrated yeast-based antibody discovery, maturation and production platform, today announced the appointment of Dr. Piotr Bobrowicz as Associate Director of Strain Development. Dr. Bobrowicz comes to Adimab after leading the High Throughput Screening and Protein Expression effort at GlycoFi Inc., a wholly owned subsidiary of Merck.

In his position at GlycoFi, Dr. Bobrowicz was instrumental in integrating all aspects of strain engineering and high throughput fermentation. His group was responsible for developing the most productive and robust cell lines for the commercial production of therapeutic proteins in yeast.

"We are delighted to have Piotr join our team," says Adimab co-founder and Dartmouth professor Tillman Gerngross.

"Piotr is a true intellectual force and he was a key contributor to GlycoFi's technical success. His keen insight and experience have earned him a loyal following at GlycoFi and we are very pleased to see him join us now at Adimab," Gerngross further explains.

"Dr. Bobrowicz's broad knowledge of applied yeast genetics and his creative spark will add tremendously to the horsepower of Adimab's scientific efforts. We were fortunate to attract him," adds Dane Wittrup, Adimab co-founder and MIT professor.

"Adimab's technology combines the best expertise in yeast engineering with a breakthrough approach to antibody discovery and maturation. I am thrilled to be part of this team. The prospects for this technology are immense," says Dr. Bobrowicz.

About Adimab, Inc.

Adimab is changing the discovery, maturation and production of therapeutic human antibodies. By integrating all aspects of antibody discovery and developing sophisticated screening methods, Adimab can rapidly select for high affinity antibodies that also behave well in formulation and manufacturing context. Our proprietary library design and presentation technology allows us to discover full-length human antibodies with broad epitope coverage and high affinity faster than any current technology. For more information, visit www.adimab.com.

###

Contact
Errik B. Anderson
VP Operations & Finance
Adimab, Inc.
(603) 727-7107
errik.anderson@adimab.com